'It's about time you get a job.' is the most deflating thing to tell me when I share my excitement of finally being able to apply for jobs after being THE one running around with my aunt every weekday to the hospital for chemoradiation the past 4 months but ok I guess. 💀

ASCRS_1 # Kurt Melstrom presenting poster eP575 - Characteristics and Outcomes of #RectalCancer Patients Who Undergo #Neoadjuvant #Chemoradiation and #RefuseSurgery after #InompleteClinicalResponse City of Hope City of Hope Surgical Oncology

Patients with locally advanced #rectalcancer now have options— outcomes in the #PROSPECT trial were non-inferior for forgoing radiation ☢️ vs. standard chemoradiation. Kudos to Deborah Schrag and the study team on this important plenary data!!! #ASCO23

Are you ready to get leaner and feel great? Don't waste any more time feeling bloated and lethargic. Try this remedy for a flat stomach and feeling of lightness every morning! I was shocked at the results after just a few weeks. My trainer recommended it to me after my workout

Finding the right treatment when living with a health condition like chronic myeloid leukemia (CML) can be challenging. Learn how Al navigated his CML treatment journey and found the right fit for him.

#NovartisCollaborator

#chronicmyeloidleukemia #Cancer #Leukemia

Really enjoyed yesterday’s talk by UT Center for Computational Oncology member David Hormuth during the #ISMRM23 Evaluating Therapeutic Response session: “Effect of chemoradiation on high-grade gliomas can be forecasted by mid-treatment images via image-driven mathematical modeling”. Cool stuff!

Great talk and noteworthy results presented by dr Elena Palassini today at #ASCO2023 #sarcoma oral abstract session.
Concurrent #chemoradiation in high-risk STS is feasible and effective

Italian Sarcoma Group GEIS Istituto Tumori

#ASCO2023 day 4 #rarecancers

ASCO Daily News interviews #ASCO23 Plenary Session presenter Dr. Deb Schrag to gain insights regarding some of the key takeaways from the PROSPECT study.

dailynews.ascopubs.org/do/asco23-plen…

ASCO Memorial Sloan Kettering Cancer Center Dr. Nina Niu Sanford Shaalan Beg
#RectalCancer #ColonCancer #crcsm

Latest project w/ University of Washington Radiation Oncology
Fred Hutchinson Cancer Center-
Independent Association of Metabolic Tumor Response on FDG-PET with Pulmonary Toxicity Following Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer: Inherent Radiosensitivity or Immune Response?
authors.elsevier.com/c/1hCyI_3qCvXT…

We Karkinos Healthcare shared strong and exciting data on “Predictive molecular marker of Chemoradiation Resistance in Cervical Cancer” ASCO
ascopubs.org/doi/abs/10.120…

We interviewed Matthew P Deek, MD, while at #ASCO23 to learn more about his analysis of NRG RTOG 0524 and 0712 regarding the prognostic significance of pretreatment immune cell infiltration in #MIBC treated with definitive chemoradiation. Watch now: buff.ly/3WZesua

Smitha Krishnamurthi, MD, and Deb Schrag, MD, MPH, on Rectal Cancer: New Findings on Chemoradiation, Chemotherapy, and Excision ascopost.com/videos/2023-as… #crcsm #rectalcancer #oncology #ASCO23 Deborah Schrag Memorial Sloan Kettering Cancer Center Smitha Krishnamurthi

Elliot Servais, MD, FACS Sandip Patel MD Santhosh Ambika Patrick Forde AATS National Comprehensive Cancer Network (NCCN) H. Jack West, MD Jonathan Spicer MD PhD Heather Wakelee Brendon Stiles Charu Aggarwal, MD, MPH A/Prof Gavin Wright Ben Solomon We did a small trial of CRT-IO and surgery and, yeah, needs more exploration for safety if it has any legs at all.

pubmed.ncbi.nlm.nih.gov/35815318/

Conversamos com ele sobre o artigo “Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation”, publicado no Journal of Clinical Oncology (JCO), em janeiro de 2023.

Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation OncoAlert ASCO Oncology Brothers LungCancerRx 🫁💊 Sandip Patel MD Stephen V Liu, MD Sanjay Popat H. Jack West, MD Jarushka Naidoo Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Aakash Desai, MD, MPH Where did neoadjuvant concurrent chemoradiation come from? And if you're not giving IO then there is no benefit of neoadjuvant chemo over adjuvant chemo.

Of all my LC symptoms(seizures, migraines, dysautonomia, anhedonia, brain fog…), Post-Exertional Malaise(PEM) has been the most disabling, life-altering symptom.

PEM is like wearing a shock collar except the shock is aggressive chemoradiation and goes off when you do anything.

Meg Madison Thanks!

I hope your chemoradiation is going as well as can be. Very tough days 💙

From our #EditorsChoice collection 'Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities' ow.ly/yBvu50OnvTj

PROSPECT trial
DOI: 10.1056/NEJMoa2303269

➡️cT2/cT3 Mid-rectal cancers
➡️Feasible for Sphincter saving Sx

➡️Non-inferiority of Preop FOLFOX*6 cycles vs Chemoradiation 👏

NEJM OncLive.com Targeted Oncology Ind J Med Ped Oncology Young Oncologists Group India🇮🇳 Dr Rajesh Bollam Rakesh Reddy Boya Dr Amol Akhade

When my husband returns from his long business trip, I will always remember the smile on his face. I dropped from 207 to 125 in this short period, and I feel healthier than ever. The next few days, we couldn't tear ourselves away from each other💕 And this is how I achieve this:

Squeezebox Best wishes to BOTH of you! I see that by itself, chemo rarely cures esophageal cancer so it is often given with radiation therapy (called chemoradiation); Is that what he's going to be treated with?

(I actually first wrote 'tweeted with.' 🙄)

The PROSPECT trial NEJM #ASCO23 suggests de-escalation of treatment for locally advanced rectal cancer - using chemoradiation selectively - does not compromise outcomes
bit.ly/3CIisGp

Aricle alter (Vol. 185)

Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer
Evan D.H. Gates et al.

doi.org/10.1016/j.rado…

Concurrent neoadj #chemoradiation therapy is safe and may increase #sarcoma #response in a clinical trial from Italian Sarcoma Group GEIS presented by dr Elena Palassini #ASCO23 Istituto Tumori Alessandro Gronchi